Since then, it has been used on several other bacterial vaccines.

Some products that may interact with this drug include: live bacterial vaccines.

Bacterial vaccine are sterilized at 60 c for an hour.

There are two types of live bacterial vaccines that can be made:

Inactivated bacterial vaccine is used during pregnancy for women who have a specific risk of exposure and disease.

Bacterial vaccines, like the one to prevent whooping cough, pose a different problem.

One conventional method of making bacterial vaccines is to use killed bacteria to stimulate the body's immune system.

Ty21a is a live attenuated bacterial vaccine that protects against typhoid.

This product may cause live bacterial vaccines (such as typhoid vaccine) not to work as well.

To be avoided are live virus and bacterial vaccines, including those for measles, mumps, rubella and chicken pox.

The first bacterial vaccine was developed by Parke-Davis, and the company was thus known as a pioneer in the field of Vaccinology.

Recombination technology that produces genetically detoxified vaccine is expected to grow in popularity for the production of bacterial vaccines that use toxoids.

This drug should not be used with certain live bacterial vaccines (e.g., BCG, typhoid) because the vaccines may not be effective.

Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription/herbal products you may use, especially of: digoxin, live bacterial vaccines, penicillins, warfarin.

Most viral vaccines are based on live attenuated viruses, while many bacterial vaccines are based on acellular components of micro-organisms, including harmless toxin components.

It is noted for developing veterinary and human vaccines for foot-and-mouth disease, rabies, bacterial vaccines, canine vaccines, hepatitis, measles, MMR and DPT.

The Food and Drug Administration calculates that at the worst the risk of contracting the disease from one dose of a bacterial vaccine, such as a vaccine to protect against tetanus, is one in 40 million.

Areas of expertise include: bacterial vaccines, toxin therapeutics, Good Laboratory Practice (GLP) and in-vivo testing of compounds, biodefence and biosafety testing, diagnostics, and the provision of cell cultures.

Since many antigens derived from acellular vaccines do not strongly induce the adaptive response, most bacterial vaccines are provided with additional adjuvants that activate the antigen-presenting cells of the innate immune system and maximize immunogenicity.

Dr. Rappuoli led Chiron Corporation's development of adjuvanted influenza vaccines, MENJUGATE(R) conjugate vaccine against meningococcal-C disease and the first recombinant bacterial vaccine against pertussis.

Top quality research at KTL included early work on interferons by Kari Cantell, research on several bacterial vaccines by Pirjo Mäkelä's group, and collaboration with the World Health Organisation to promote vaccination programs in developing countries.